AMRX
Amneal Pharmaceuticals, Inc.
20.30$
+1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.8% | -0.5% | +1.5% | -1.4% | +1.2% | -3.9% | +1.7% | +5.2% | +2.2% | -3.8% | +6.7% | |
| – | -5.4% | +0.2% | +7.6% | +1.9% | +4.9% | -4.9% | +4.9% | +16.0% | +4.0% | -5.9% | +8.3% | |
| – | +5.3% | -47.1% | -9.7% | +69.1% | +49.4% | -46.5% | +37.2% | +147.9% | +54.5% | -36.4% | -35.4% | |
| – | +1.8% | -48.3% | -2.6% | +56.7% | +51.9% | -47.4% | +37.2% | +147.9% | +54.5% | -36.4% | -35.4% | |
| – | -6.6% | +9.0% | +14.1% | -2.1% | -1.3% | +3.2% | +6.1% | +8.8% | +1.7% | -4.0% | +13.1% | |
| – | +0.9% | -1.8% | +0.9% | +3.6% | +2.7% | -1.8% | +1.3% | +0.9% | -1.3% | +5.8% | +5.7% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | -0.1% | +0.0% | 0.0% | -0.2% | -0.1% | -0.3% | -0.1% | |
| – | -9.4% | -3.5% | -4.6% | -4.8% | -6.1% | -5.9% | -5.7% | -9.5% | -4.2% | -5.1% | +9.9% | |
| – | -2.4% | +1.8% | +1.2% | -0.6% | +1.5% | -3.4% | +1.3% | +6.9% | -1.0% | -2.3% | +2.0% | |
| – | +11.3% | -1.4% | +33.6% | -1.7% | +3.2% | -4.8% | +2.9% | -22.1% | +2.3% | -17.4% | +21.3% | |
| – | +85.8% | +0.5% | +97.5% | -15.6% | -10.7% | -0.8% | -0.6% | -93.6% | +0.5% | -0.4% | +465.1% | |
| – | -19.1% | +22.1% | +13.8% | +17.7% | +10.6% | -25.9% | +246.3% | -60.1% | -4.4% | -10.6% | +7.3% | |
| – | -6.0% | -0.3% | -10.0% | -0.4% | -0.4% | -0.4% | -0.4% | +19.6% | -0.1% | +0.0% | 0.0% | |
| – | -94.0% | -422.1% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +52.6% | +26.1% | +3.8% | -2.9% | +0.1% | +4.6% | -0.5% | +0.7% | +0.0% | +1.3% | -0.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.